Lin S - Search Results

1

Correction: circular RNA circATP9A promotes non-small cell Lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization.

Yao Y, Chen C, Wang J, Xuan H, Chen X, Li Z, Yang F, Wang B, Lin S, Li S, Tang D, Gong L, Gao W. Yao Y, et al. Among authors: lin s. J Exp Clin Cancer Res. 2023 Dec 19;42(1):345. doi: 10.1186/s13046-023-02924-6. J Exp Clin Cancer Res. 2023. PMID: 38111017 Free PMC article. No abstract available.

2

Circular RNA circATP9A promotes non-small cell lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization.

Yao Y, Chen C, Wang J, Xuan H, Chen X, Li Z, Yang F, Wang B, Lin S, Li S, Tang D, Gong L, Gao W. Yao Y, et al. Among authors: lin s. J Exp Clin Cancer Res. 2023 Dec 5;42(1):330. doi: 10.1186/s13046-023-02916-6. J Exp Clin Cancer Res. 2023. PMID: 38049814 Free PMC article.

3

The promotion of non-small cell lung cancer progression by collagen and calcium binding EGF domain 1 is mediated through the regulation of ERK/JNK/P38 phosphorylation by reactive oxygen species.

Chen C, Tang D, Xu S, Xiang L, Wang B, Yao Y, Li Z, Lin S, Li S, Shi X, Gu C, Gao W. Chen C, et al. Among authors: lin s. Mol Carcinog. 2024 Aug;63(8):1467-1485. doi: 10.1002/mc.23736. Epub 2024 May 10. Mol Carcinog. 2024. PMID: 38726928

4

Telocytes protect against lung tissue fibrosis through hexokinase 2-dependent pathway by secreting hepatocyte growth factor.

Zhang S, Sun L, Chen B, Lin S, Gu J, Tan L, Lin M. Zhang S, et al. Among authors: lin s, lin m. Clin Exp Pharmacol Physiol. 2023 Dec;50(12):964-972. doi: 10.1111/1440-1681.13823. Epub 2023 Sep 16. Clin Exp Pharmacol Physiol. 2023. PMID: 37715611

5

Fibroblast growth factor 10 attenuates chronic obstructive pulmonary disease by protecting against glycocalyx impairment and endothelial apoptosis.

Jiang T, Hu W, Zhang S, Ren C, Lin S, Zhou Z, Wu H, Yin J, Tan L. Jiang T, et al. Among authors: lin s. Respir Res. 2022 Oct 1;23(1):269. doi: 10.1186/s12931-022-02193-5. Respir Res. 2022. PMID: 36183124 Free PMC article.

6

Association of LAMA1 Single-Nucleotide Polymorphisms with Risk of Esophageal Squamous Cell Carcinoma among the Eastern Chinese Population.

Zhang S, Fang Y, Su F, Jiang T, Yu J, Lin S, Lv L, Long T, Pan H, Qi J, Zhou Q, Tang W, Ding G, Wang L, Tan L, Yin J. Zhang S, et al. Among authors: lin s. J Oncol. 2023 Feb 14;2023:6922909. doi: 10.1155/2023/6922909. eCollection 2023. J Oncol. 2023. PMID: 36824663 Free PMC article.

7

Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial).

Yin J, Lin S, Fang Y, Jiao H, Chen Z, Tang H, Gu J, Zhang S, Sun L, Li Y, Han Y, Chen Q, Chen H, Li Z, Tan L. Yin J, et al. Among authors: lin s. J Thorac Dis. 2023 Feb 28;15(2):718-730. doi: 10.21037/jtd-22-1789. Epub 2023 Feb 8. J Thorac Dis. 2023. PMID: 36910109 Free PMC article.

8

The Single Nucleotide Polymorphisms of AP1S1 are Associated with Risk of Esophageal Squamous Cell Carcinoma in Chinese Population.

Su F, Fang Y, Yu J, Jiang T, Lin S, Zhang S, Lv L, Long T, Pan H, Qi J, Zhou Q, Tang W, Ding G, Wang L, Tan L, Yin J. Su F, et al. Among authors: lin s. Pharmgenomics Pers Med. 2022 Mar 17;15:235-247. doi: 10.2147/PGPM.S342743. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35321090 Free PMC article.

9

Publisher Correction: Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.

Yin J, Yuan J, Li Y, Fang Y, Wang R, Jiao H, Tang H, Zhang S, Lin S, Su F, Gu J, Jiang T, Lin D, Huang Z, Du C, Wu K, Tan L, Zhou Q. Yin J, et al. Among authors: lin d, lin s. Nat Med. 2023 Sep;29(9):2376. doi: 10.1038/s41591-023-02511-4. Nat Med. 2023. PMID: 37507607 Free PMC article. No abstract available.

10

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.

Yin J, Yuan J, Li Y, Fang Y, Wang R, Jiao H, Tang H, Zhang S, Lin S, Su F, Gu J, Jiang T, Lin D, Huang Z, Du C, Wu K, Tan L, Zhou Q. Yin J, et al. Among authors: lin d, lin s. Nat Med. 2023 Aug;29(8):2068-2078. doi: 10.1038/s41591-023-02469-3. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488287 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31,939 results

Search Page

Filters